(Additional fee required, seating limited)
Sunday, March 12
7 a.m. – 5 p.m.
The AUTM Technology Valuation CourseSM teaches technology valuation as specifically applied to academic licensing. The first portion of the course reviews key concepts such as value creation, accounting measurements and key license terms that affect value and risk. It then reviews basic valuation methodologies, including cost, industry standards, comparables, profit allocation, discounted cash flow and equity. The first part concludes with a review of payment structures within a license.
The second portion of the course consists of case studies derived from real world examples. The class will be divided into groups to develop license term proposals, which will then be discussed by the class. If you have or will have responsibility for negotiating licenses, the AUTM Technology Valuation CourseSM is for you.
Registrants should have a basic familiarity with the structure and payment mechanisms used in a license, an intermediate level of experience in license negotiations and basic knowledge of the valuation methodologies that are reviewed in the first half of the course. As a pre-requisite for the course, all attendees should have participated in the four webinars presented in the AM17 Valuation Course - Pre-requisite package. Once you register for this course, you will receive an email with instructions on how to access the AM17 Valuation Course - Pre-requisite course content.
This year we are inviting participants to provide a real life case study for the class to review and provide suggestions and guidance based on the course content. If you are interested in submitting a blinded case to the teaching team for discussion during the course, please submit a one page summary of the case via email to firstname.lastname@example.org before February 15, 2017. If your case is selected by the course faculty, you will be contacted prior to the course. Please do not send any information of a confidential or proprietary nature.
7 - 8 a.m. Continental Breakfast
8 - 8:45 a.m. Creating Value - Overview and Discussion
8:45 - 9:30 a.m. Measuring Value - Overview and Discussion
9:30 - 10:15 a.m. Capturing Value - Overview and Discussion
10:15 - 10:45 a.m. Networking Break
10:45 - 11:30 a.m. Startups - Overview and Discussion
11:30a.m. - Noon Group Team Building - Case Study Introductions
Noon - 1 p.m. Lunch provided
1 -2 p.m. Case Study Review
2-3 p.m. Case Study Discussion
3 - 3:30 p.m. Networking Break
3:30 - 5 p.m. Case Study Discussion (continued)
Steven M. Ferguson currently serves as Special Advisor for Technology Transfer for the NIH Office of Technology Transfer where he has worked since 1990. The biomedical technology transfer program at NIH is one of the world’s largest with a portfolio that includes about 1300 active licenses, 400 of which report product sales in aggregate greater than $6B per year. A former chemist at the National Cancer Institute and biotech industry product manager, Mr. Ferguson holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor’s Degree in Chemistry (Case Western Reserve University). A registered Patent Agent and a Certified Licensing Professional (CLP), Mr. Ferguson is faculty and Technology Transfer Department Chair at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH and the Biotechnology Industry Organization “BIO Boot Camp” along with being an Executive-in-Residence at the Johns Hopkins University Cary School of Business. He has received the AUTM President’s Award (AUTM Band), the NIH Director’s Award, the FAES Instruction Award, three “Deal of Distinction” awards from the Licensing Executive Society, six Federal Laboratory Consortium Awards, and fifteen NIH Merit Awards in recognition of his service and activities in the area of technology transfer.
Andrew J. Maas is the Assistant Vice President for Research and Director of the Office of Innovation & Technology Commercialization at Louisiana State University. Andy is an engineer by training with a BS and MS in Civil Engineering from Brigham Young University and the University of Texas at Austin, respectively. He is a licensed professional engineer in the state of Texas where he worked for several years and grew a start-up engineering company from two individuals to 14 employees. Andy also has a JD from the University of Akron School of Law, as well as a LLM with a focus on intellectual property. His research focus for his LLM degree was "early stage patent valuation under the new America Invents Act." He has been published in the Journal of the United States Patent and Trademark Office, as well as in Cement and Concrete Research.
Rekha K. Paleyanda is the Director of the Office of Technology Commercialization at the University of Massachusetts in Lowell. She has extensive experience in identifying new product opportunities, negotiating licenses with startups and established companies, as well as managing a range of strategic alliances with industry partners. She works closely with inventors to develop commercialization plans for their technologies. She comes to UML after ten years in strategic IP portfolio management and licensing and building corporate relationships at MGH, Partners Healthcare, Boston. Prior to that Rekha co-founded and led strategic and business development at a startup, AI Biologics, and worked in R&D developing therapeutics for rare genetic diseases at Transkaryotic Therapies, now part of Shire plc. She has published several research papers, is inventor of several patents and lectures on IP policy, licensing and partnering. She received a Ph.D. from the George Washington University in Washington D.C. and conducted postdoctoral research at the Holland Lab for Biomedical Sciences in Rockville, Maryland.
Ashley J. Stevens, D.Phil (Oxon), CLP, RTTP, is president of The Focus IP Group, which provides a variety of consulting services in intellectual property matters, including serving as an Expert Witness in intellectual property disputes, technology scouting, technology transfer and teaching the commercialization of early stage technologies.
For 15 years, Dr. Stevens led Boston University’s Office of Technology Transfer. He then became Special Assistant to the Vice President for Research for two years before retiring from full time employment at BU. For ten years he was a Lecturer in the Strategy and Innovation Department in Boston University’s Questrom School of Business, where he taught two graduate-level, inter-disciplinary courses on Technology Commercialization. Before joining Boston University he was Director of the Office of Technology Transfer at the Dana-Farber Cancer Institute, a teaching affiliate of the Harvard Medical School.
During his tenure at Boston University, the Office of Technology Development spun out over 50 companies based on the University’s research, a number of which raised substantial amounts of capital, and the University’s licensing income climbed steadily.
He is a Guest Professor at Osaka University, Japan, where he teaches G-TEC, an intensive summer course on technology commercialization, and a Principal Investigator at the National University of Singapore (Suzhou) Research Institute, where he teaches professional development courses on technology management. He has also taught in Belgium, Canada, Chile, China, Colombia, India, Holland, Korea, Saudi Arabia, Singapore, S. Africa and Thailand.
Prior to entering the technology transfer profession, Dr. Stevens worked in the biotechnology industry for nearly ten years. He was a co-founder of Kytogenics, Inc. and Genmap, Inc., and was Vice President of Business Development for BioTechnica International. He started his career with The Procter & Gamble Company, where he held a number of positions in commercial development, sales, marketing, product management, strategic planning and acquisitions and mergers.
Dr. Stevens publishes and lectures frequently on many aspects of technology transfer, including the Bayh-Dole Act, the economic impact of technology transfer and its role in economic development, the contribution of academia to the discovery of new drugs, vaccines and medical devices, the role of technology transfer in global health and technology valuation. He was the recipient of the Bayh-Dole Award at the Association of University Technology Managers (AUTM) 2007 Annual Meeting and became President of AUTM in March 2010. He is also active in the Licensing Executives Society.
Dr. Stevens holds a Bachelor of Arts in Natural Sciences, a Master of Arts and a Doctor of Philosophy in Physical Chemistry from Oxford University. He is a Certified Licensing Professional and a Registered Technology Transfer Professional.